The FDA Just Let ZYN Say It's Safer Than Cigarettes. The Brain Circuit That Makes That Technically True Is Also Why Quitting Nicotine Pouches Is Its Own Fight.

If you’ve ever tried to quit nicotine and found that the craving didn’t arrive as a gentle suggestion but as something closer to a physical demand, you weren’t imagining the intensity. There’s a specific, named circuit in your brain built to make that demand feel non-negotiable — and, as of this week, a federal agency has just made it easier to buy the product engineered to satisfy it.

The FDA didn’t just approve a marketing claim for ZYN. It ratified a bet that half of nicotine’s brain circuitry — the half that makes quitting brutal — matters less than the half that makes cigarettes deadlier, and that bet is defensible science wrapped around an incomplete sentence.

What the FDA actually authorized, and what it didn’t

On June 30, the FDA’s Center for Tobacco Products authorized 20 ZYN nicotine pouch products — 10 flavors across 3mg and 6mg strengths — to carry a specific label claim for the first time in the product category’s history: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” This is a Modified Risk Tobacco Product designation, a formal FDA pathway that requires the manufacturer to prove the claim is accurate and that it won’t mislead people into thinking the product is risk-free or a reasonable thing for a nondependent person to start using. As US News reported, critics — public health researchers who track youth nicotine trends — immediately warned that a federally sanctioned “safer” label is exactly the kind of signal that normalizes and expands use among people who were never smokers to begin with, teenagers especially.

Both things are true. Swapping a lit cigarette, which delivers thousands of combustion byproducts including known carcinogens, for an oral pouch that delivers nicotine without smoke, is a real reduction in several specific, measurable disease risks. That is not spin; it’s pharmacology and toxicology doing what they’re supposed to do. What the claim doesn’t say — because it isn’t required to, and because “safer than cigarettes” is not the same sentence as “safe” — is that the nicotine itself, delivered by any route, is still doing the same thing to your brain that it always did. Understanding that mechanism is the part of this story that gets lost between a press release and a pouch tin.

We have watched a “safer” tobacco claim get official sanction before, and it didn’t end well. Starting in the 1970s, cigarette makers marketed “light” and “low-tar” cigarettes with government-permitted machine-testing numbers that implied meaningfully reduced harm — numbers smokers reasonably read as medical reassurance. Decades later, research showed smokers compensated by inhaling harder and smoking more of each cigarette to get the nicotine dose they were dependent on, erasing much of the measured benefit, and Congress banned the descriptors entirely in the 2009 Family Smoking Prevention and Tobacco Control Act. The ZYN claim is built on real toxicology and a formal FDA review process the “light cigarette” era never had — a meaningfully higher bar. But the underlying risk is the same shape: a “safer” label doesn’t stop a dependent brain from finding a way to get its usual dose.

Two circuits, one molecule: reward and aversion aren’t the same wire

Nicotine’s addictive grip runs through a receptor most people have never heard of, called the nicotinic acetylcholine receptor — think of it as a lock that nicotine fits into, scattered across specific brain regions, that normally responds to your body’s own signaling chemistry and gets hijacked by an outside molecule shaped just closely enough to fit. The version of that lock nicotine binds most strongly, called the α4β2 receptor, sits in a reward pathway running between the ventral tegmental area and the nucleus accumbens — the same general reward circuitry implicated in most substances people struggle to quit. Trigger it, and your brain registers a hit of the pleasure-and-relief signal that makes the next pouch, cigarette, or vape feel worth reaching for.

Here’s the part that’s genuinely new, and genuinely useful, in explaining why nicotine dependence has its own particular shape: there’s a second, separate circuit, running through a different version of the same receptor family (built around what’s called the α5 subunit) in a brain region called the medial habenula, that does close to the opposite job. According to research summarized in Frontiers in Neuroscience, this circuit fires in a distinct burst pattern that releases GLP-1 — yes, the same signaling molecule behind Ozempic and Wegovy — into a downstream brain region called the interpeduncular nucleus, producing aversion and driving the tolerance that makes a satisfying dose creep upward over time. One circuit says “more, now.” A separate one, using a hormone currently famous for entirely different reasons, says “that’s enough, and next time it’ll take more to feel the same.” Nicotine dependence is what happens when you spend years training the first circuit to win the argument.

That dual-circuit model explains something clinicians see constantly and rarely have a clean mechanism to point to: why nicotine tolerance escalates so predictably, and why the physical unpleasantness of “too much” nicotine (nausea, racing heart, lightheadedness) doesn’t reliably stop escalating use the way it seems like it should. The aversion circuit is real. It’s also outgunned.

The dependence data the modified-risk claim doesn’t have to mention

None of this shows up in a modified-risk label, because the label is about disease risk, not dependence severity — and the dependence side of the ledger has gotten worse, not better, even as the products have gotten technically less toxic. Truth Initiative’s most recent market analysis found nicotine pouch sales nearly tripled, from $145 million to $404 million, between January 2023 and December 2024, while total nicotine sold across e-cigarette products rose 249% since 2020 as concentrations climbed. The dependence-severity markers moved in the same direction: the share of daily teen e-cigarette users who tried and failed to quit rose from 28.2% in 2020 to 53% in 2024, and 76% of teens who vape now do so within 30 minutes of waking — a classic clinical marker (borrowed from decades of cigarette-dependence research) for how tightly a substance has its hooks in.

If you use nicotine pouches, a vape, or cigarettes and have tried to stop, the fact that quitting felt like fighting your own body isn’t a failure of willpower — it’s two real, competing circuits in your brain, and one of them was built to win in the short term every single time. That doesn’t mean quitting is impossible; it means the aversion circuit that should be helping you needs backup, which is exactly what nicotine replacement therapy, varenicline, and behavioral counseling are designed to provide.

For providers, the actionable read is this: the ZYN modified-risk claim is a genuinely useful tool for counseling patients who are currently smoking and unwilling or unable to quit nicotine outright — harm reduction, correctly applied, meets people where they are. It is not a tool for a patient who isn’t already a combustible-tobacco user, and it says nothing about how hard that patient will find it to eventually put the pouch down too. Screen for nicotine dependence the way you’d screen for any other substance, regardless of which product delivered it, and don’t let a modified-risk label substitute for that conversation.

Screen for nicotine dependence the way you’d screen for any other substance, regardless of which product delivered it, and don’t let a modified-risk label substitute for that conversation.

For more on the shifting nicotine and vaping landscape, see our nicotine-tobacco coverage and our earlier reporting connecting GLP-1 mechanisms to craving across substance classes.